Cancer epigenetics is developing into one of the most promising and rapidly developing fields in oncology. It reveals mechanisms by which cancer genes are deregulated, provides novel tumor biomarkers to identify and target the cell of origin of a given tumor, and can be exploited to predict cancer risk. Notably, current large-scale cancer genome sequencing efforts have discovered a surprisingly large number of cancer-specific mutations in regulators of the epigenome. The high relevance of epigenetics for cancer goes hand in hand with the development of an increasing number of epigenetic drugs used in cancer therapy. Inspired by the success of the ‘1st European Cancer Epigenetics Conference’ in Maastricht in 2015, we are inviting researchers to the 2nd symposium to continue exploring this exciting field.
- 2nd European Cancer Epigenetics Conference